您的位置: 百康网 > 期刊 > 皮肤病学与性病学 > 《皮肤病在线杂志》 > 2006年5月第5期 > 正文
Giant clear cell acanthoma with keratoacanthoma-like changes: A case report
 本页关键词:A
2007-6-14 16:32:29

  Abstract

  Clear cell acanthoma is a benign epidermal lesion with a variable clinical appearance and distinct histopathology features. Although, it is considered an entirely benign entity, few case reports describe unusual or atypical variants of clear cell acanthoma. We observed a case of a large clear cell acanthoma that also has features of a keratoacanthoma.

  Introduction

  Clear cell acanthoma (CCA), first described by Degos [1] in 1962, presents as a well-demarcated, solitary red nodule or plaque several millimeters to 2 cm in diameter. Histologically, it is characterized by psoriasiform epidermal hyperplasia comprised of pale keratinocytes that contain abundant glycogen in their cytoplasm. This glycogen can be highlighted with a PAS stain and digested with addition of diastase. Neutrophils may also be seen in the epidermis, and the blood vessels of the dermal papillae may be dilated. These histopathologic changes are usually well demarcated from the uninvolved adjacent epidermis.

  The majority of reported cases have this typical appearance. Several authors have reported morphologic variants of CCA that show additional features, including giant, polypoid, pigmented, and cystic forms [2-9]. Other authors reported cytologic atypia and increased mitotic figures in cases of CCA [10, 11]. In this report we describe a giant clear cell acanthoma with changes analogous to those seen in keratoacanthoma.

  Clinical synopsis

  The cytoplasm of the pale cells was positive for periodic-acid-Schiff (PAS) (Fig. 4) and the staining was removed by diastase digestion (PAS-D) (Fig. 5) indicating that these cells were rich in glycogen.

  Centrally, an endophytic component extending deep into the dermis displayed cystic change with formation of a crater-like structure filled with parakeratotic debris (Fig. 6). The epidermis of this deeper part of the tumor was more irregularly hyperplastic, and comprised of keratinocytes with slightly enlarged nuclei with small nucleoli and eosinophilic (glassy) cytoplasm (Fig. 7). Scattered squamous eddies surrounding small parakeratotic plugs were also observed (Fig. 8). The deep atypical areas of this lesion showed less intense reactivity with a PAS stain (Fig. 9). This endophytic portion of the lesion was surrounded by broad zones of dermal fibrosis, a chronic inflammatory cell infiltrate and scattered siderophages.

  In summary, this lesion has two components—a peripheral exophytic component with features of clear cell acanthoma and a central endophytic component with features similar to those described in classic keratoacanthoma [12]. Therefore, we rendered the following diagnosis for this case: An exoendophytic proliferation of keratinocytes with features of a keratoacanthoma and a clear cell acanthoma.

  Discussion

  Degos was the first to describe CCA in 1962 and in 1970, he published an article summarizing an 8 year experience with this entity based on more than 140 cases recorded in the literature up to that time [1]. Most of the cases of CCA occur between the ages 50 and 70. The majority are solitary and occur on the lower limb. The average diameter ranges between 10 and 15 mm. The clinical appearance is variable. The lesions may be clinically interpreted as keratoses, warts, eccrine poromas, hemangiomas or carcinomas. The typical histology is that of a psoriasiform epidermal hyperplasia composed of keratinocytes with pale cytoplasm. These pale keratinocytes contain abundant glycogen, and this lesion shows a clear demarcation from the adjacent epidermis. There may be some spongiosis, a parakeratotic scale and an inflammatory infiltrate in dermis.

  Many cases that deviate from this classic description of CCA have been reported including giant [2, 8], polypoid [4, 6, 7, 9], pigmented [5], and cystic [3] morphologic variants.

  In addition to these clearly benign variants, a few cases have been reported that describe cytologic atypia and increased mitotic figures in what otherwise looks like a classic CCA. One case report described a lesion that had an area of epidermal cytologic atypia spanning the full thickness of the epidermis. The remainder of that lesion showed changes of classic CCA. That case was diagnosed as a squamous cell carcinoma in-situ arising within a CCA [11]. In another paper, cytologic atypia and atypical mitotic figures were noted in two cases of CCA. For these two cases, the authors preferred to use the term atypical CCA rather than malignant CCA because no recurrence or metastasis had been observed during 4 and 5 year followups [10].

  Here we report a case of a large polypoid tumor (3 cm) from the groin of a 45-year-old man. Clinically it was suspected to be a carcinoma or a giant condyloma. Microscopic examination revealed an exophytic component with features of CCA. Centrally, however, the tumor had an endophytic component that exhibited features of a keratoacanthoma with a crater-like cystic space and a surrounding jagged epidermal border comprised of large keratinocytes with glassy eosinophilic cytoplasm, and squamous eddies, and surrounded by an inflammatory infiltrate and fibrosis. We did not observe marked cytologic atypia or atypical mitotic figures in this lesion.

  In conclusion, our findings are those of keratinocytic proliferation that has grown for years to a very large size. In some areas this lesion has the appearance of a classic CCA. In other areas there are cytoarchitectural features of a keratoacanthoma. Our interpretation is that this lesion represents a large CCA that contains a central area of malignant degeneration.

  References

  1. Degos, R. and Civatte, J. Clear-cell acanthoma. Experience of 8 years. Br J Dermatol. 1970 Aug;83(2):248-54. PubMed

  2. Duperrat, B., Vanbremeersch, F., David, V., Mascaro, J. M. and Bedard, A. [Giant form of the acanthoma of Degos]. Bull Soc Fr Dermatol Syphiligr. 1966 Dec;73(6):884-6. PubMed

  3. Hamaguchi, T. and Penneys, N. Cystic clear cell acanthoma. J Cutan Pathol. 1995 Apr;22(2):188-90. PubMed
 
  4. Inaloz, H. S., Patel, G. and Knight, A. G. Polypoid clear cell acanthoma: case report. J Eur Acad Dermatol Venereol. 2000 Nov;14(6):511-2. PubMed

  5. Langer, K., Wuketich, S. and Konrad, K. Pigmented clear cell acanthoma. Am J Dermatopathol. 1994 Apr;16(2):134-9. PubMed

  6. Nijssen, A., Laeijendecker, R., Heinhuis, R. J. and Dekker, S. K. Polypoid clear cell acanthoma of unusual size. J Am Acad Dermatol. 2001 Feb;44(2):314-6. PubMed

  7. Petzelbauer, P. and Konrad, K. Polypous clear cell acanthoma. Am J Dermatopathol. 1990 Aug;12(4):393-5. PubMed

  8. Roytman, M., Frumkin, A. and Everett, M. A. Giant clear cell acanthoma. J Am Acad Dermatol. 1987 Sep;17(3):513-4. PubMed

  9. Wilde, J. L., Meffert, J. J. and McCollough, M. L. Polypoid clear cell acanthoma of the scalp. Cutis. 2001 Feb;67(2):149-51. PubMed

  10. Grunwald, M. H., Rothem, A. and Halevy, S. Atypical clear cell acanthoma. Int J Dermatol. 1991 Dec;30(12):848-50. PubMed

  11. Parsons, M. E. and Ratz, J. L. Squamous cell carcinoma in situ arising within clear cell acanthoma. Dermatol Surg. 1997 Jun;23(6):487-8. PubMed

  12. LeBoit, P. E. Can we understand keratoacanthoma? Am J Dermatopathol. 2002 Apr;24(2):166-8. PubMed

 



查询更多A相关信息在本站>>

  

《皮肤病在线杂志》2006年5月第5卷第5期 

评论】【打印】【 】【关闭
相关文章
Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy for Medullary Thyroid Carcinoma
Induction of Tolerance in Autoimmune Diseases Rather Than Cure of Cancer by Interleukin-2 Therapy
BRCA1 and BRCA2 Cancer Risks
Optimal Selection of Individuals for BRCA Mutation Testing
Normal CA-125 and the Risk of Progression in Ovarian Cancer
Comparison of Outcomes in Studies of Advanced Hodgkin's Lymphoma
Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function
Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors
Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carb
Phase III Trial of Intraperitoneal Therapy With Yttrium-90–Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete Remission